Last call for marketing authorisation holders to submit information about in-use shelf life of OTC medicinal products
Marketing authorisation holders are obliged to include information about the in-use shelf-life of OTC medicinal products in the product information. As a marketing authorisation holder, you must have stated to the Medicines Evaluation Board (MEB) no later than 30 September 2017 how you intend to comply with this policy in respect of your OTC medicinal products.
The MEB published the new policy on including information about in-use shelf life of OTC medicinal products (MEB 46) on 30 September 2016.
What you need to do
Marketing authorisation holders are obliged to state to the MEB when and how they intend to comply with this policy in respect of their products, if they have not yet done so. Please send an e-mail to this end to email@example.com no later than 30 September 2017, with the subject: case number 610886.
The MEB may grant postponement to marketing authorisation holders to carry out a stability study to collect information about these products.
The MEB also accepts promises from marketing authorisation holders to submit the information requested no later than a few months before a product is introduced on the market.
Marketing authorisation holders had been given until the end of March 2017 to modify the product information by submitting a variation or a notification. However, with regard to a part of the products, no information about the listing of the in-use shelf life has yet been submitted.
The policy of listing the in-use shelf life on the packaging of OTC medicinal products is now standard policy. It will be processed in the following amendment of the Labelling Policy (MEB 6).
MEB 46: Policy on listing in-use shelf life on the packaging of OTC medicinal products
An investigation carried out by the Dutch consumers’ organisation at the end of 2015 showed that the in-use shelf life is often...
MEB 6: Labelling of pharmaceutical products
The presentation of the primary and secondary packaging of a medicinal product are determining factors in the recognition of a...